Neuro-Oncology News

Approximately 16% of children with sporadic neuroblastoma harbored rare pathogenic or likely pathogenic variants in a cancer predisposition gene, most of which were inherited, according to study results.

Going through cancer during transitional adolescent and young adult years can present additional social, financial and mental health challenges that add to the stressors of diagnosis and treatment.

Childhood brain tumor survivors have a high prevalence of significant weight gain, overweight and obesity, and changes in BMI may indicate hypothalamic-pituitary dysfunction, according to a study published in Journal of Clinical Oncology.

OKN-007 received FDA fast track designation for the treatment of children with diffuse intrinsic pontine glioma, or DIPG, according to a press release from the agent’s manufacturer.

The FDA granted fast track designation to GLR2007 for treatment of glioblastoma, according to the agent’s manufacturer.

Manmeet Ahluwalia, MD, FACP, MBA, has been appointed deputy director of Baptist Health’s Miami Cancer Institute.

The FDA granted orphan drug designation to aminolevulinic acid hydrochloride, an optical imaging agent that helps visualize tumor tissue during resection of meningioma, according to a manufacturer-issued press release.

Toxoplasma gondii infection appeared to increase the risk for glioma in adults, according to study results published in International Journal of Cancer.

Low-grade glioma is a historically challenging cancer to treat, with some patients succumbing to the disease within weeks of diagnosis and others surviving for decades.

The FDA granted accelerated approval to naxitamab-gqgk for children aged 1 year or older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, according to the drug’s manufacturer.